| Dr Daniel Andrew Pietro, MD | |
|
940 Belmont St, Brockton, MA 02301-5596 | |
| (857) 203-6841 | |
| Not Available |
| Full Name | Dr Daniel Andrew Pietro |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Cardiovascular Disease |
| Location | 940 Belmont St, Brockton, Massachusetts |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1477593572 | NPI | - | NPPES |
| 3054560 | Medicaid | MA | |
| 730130 | Other | MA | TUFTS |
| J03607 | Other | MA | BC/BS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 39539 (Massachusetts) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Daniel Andrew Pietro, MD 19 Hunter Ln, Canton, MA 02021-1731 Ph: (617) 538-2324 | Dr Daniel Andrew Pietro, MD 940 Belmont St, Brockton, MA 02301-5596 Ph: (857) 203-6841 |
News Archive
Canon U.S.A., Inc., a leader in digital imaging, today announced the latest addition to the award-winning REALiS Multimedia Projector lineup, the SX7 Mark II D with DICOM Simulation Mode. In the medical-education field viewing monochrome digital X-Rays, CAT Scans and MRI's with accurate color and precise detail is of the highest importance and the REALiS SX7 Mark II D is able to meet this need on a scale much larger than traditional monitors.
NanoLogix, an innovator in the accelerated detection and identification of microorganisms, announced today that the University of Texas Health Science Center in Houston is enrolling 300 patients in an ongoing clinical trial to study the speed and accuracy of NanoLogix technology. The trial is designed to compare NanoLogix technology to current methods in use for detection and identification of Group B Streptococcus (GBS) in pregnant women.
Using a new gene-editing system based on bacterial proteins, MIT researchers have cured mice of a rare liver disorder caused by a single genetic mutation.
Algeta ASA has announced that with the results of the BC1-04 study reported today it has completed its comprehensive phase II clinical program evaluating Alpharadin (radium-223) as a new treatment for bone metastases in patients with hormone-refractory prostate cancer (HRPC).
› Verified 4 days ago
Louis D. Gottlieb, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 680 Centre St, Managed Care, Brockton, MA 02302 Phone: 508-941-7065 Fax: 508-941-6373 | |
Gloria Ibarra, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 63 Main St, Brockton, MA 02301 Phone: 508-559-6699 Fax: 508-559-5073 | |
Elsie Varughese, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 63 Main St, Brockton, MA 02301 Phone: 508-559-6699 Fax: 508-583-4649 | |
Jane G Butlin, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1 Pearl St, Suite 2200, Brockton, MA 02301 Phone: 508-897-6051 Fax: 508-897-6096 | |
Jacob Mandell, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 680 Centre St, Brockton Hospital, Brockton, MA 02302 Phone: 508-941-7150 | |
Jolly Abeskheron, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1 Pearl St, Suite 1000, Brockton, MA 02301 Phone: 508-897-6060 Fax: 508-897-6063 | |
Xin He, Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 110 Liberty St, Brockton, MA 02301 Phone: 508-894-0400 |